All-trans retinoic acid (ATRA) is now a standard agent for remission induction of acute promyelocytic leukemia (APL). Recently, extramedullary relapse, which was a rare condition in APL patients after chemotherapy alone, was reported with an increased frequency after ATRA treatment. However, it is not yet clear whether ATRA truly increases the risk of extramedullary recurrence and what are the risk factors. In this study, three of 13 patients with recurrent APL after prior treatment of ATRA were found to have extramedullary involvement, compared with none in 11 recurrent patients previously treated with chemotherapy alone (estimated relative risk 2.100, 95% confidence interval 1.341-3.289). Furthermore, in the former group of patients, the development of retinoic acid (RA) syndrome during prior induction treatment was significantly associated with extramedullary involvement at relapse (three in five patients with RA syndrome vs none in eight without the syndrome, estimated relative risk 5.000, 95% confidence interval 1.448-17.271). In conclusion, ATRA may predispose APL patients to extramedullary involvement at relapse and the occurrence of RA syndrome is a risk factor for it. Further studies are needed to confirm these findings. It also remains to be clarified whether treatment modification is necessary in patients who develop RA syndrome during ATRA treatment.
Introduction
Acute promyelocytic leukemia (APL) is a distinct subset of acute myeloid leukemia characterized by a specific balanced chromosome translocation, t(15;17)(q21;q22). The translocation results in an abnormal fusion gene, PML/RAR␣, which is considered to play an important role in the pathogenesis of APL 1 . Since the late 1980s, all-trans retinoic acid (ATRA) has been applied to the induction therapy of APL. 2 It induces complete remission (CR) in up to 85-90% of patients with newly diagnosed APL, and when combined with cytotoxic chemotherapy, it prolongs relapse-free survival and overall survival compared with conventional chemotherapy alone. 3 Although early death due to bleeding is reduced by remission induction with ATRA, a new adverse event, retinoic acid (RA) syndrome, is noted in some patients during treatment and may cause significant morbidity and mortality. 4 The syndrome usually presents with fever, respiratory distress, body weight gain and pleural-pericardial effusion. It is usually associated with hyperleukocytosis and is characterized by infiltration of maturing leukemic cells into various organs and tissues.
Recently, there has been increasing concern about the risk of extramedullary involvement of APL at relapse after prior induction treatment with ATRA. This event was rarely reported in those patients with cytogenectically and/or molecularly con- firmed APL who were treated with chemotherapy alone. [5] [6] [7] However, it is not yet clear whether ATRA truly increases the risk of extramedullary relapse and what are the risk factors. In this study, relapsed APL patients treated with or without ATRA were compared for the incidence of extramedullary involvement. Efforts were also made to find out the risk factors for the event.
Materials and methods

Patients treated with ATRA
From January 1992 to January 1996, 25 cases of de novo APL were diagnosed according to French-American-British classification at National Taiwan University Hospital. The diagnosis of all cases was confirmed by the presence of t(15;17) in conventional cytogenetic studies or PML/RAR␣ fusion transcript in reverse transcriptase polymerase chain reaction(RT-PCR). 8 The surface antigen expression of APL cells was routinely checked at diagnosis.
The patients were treated as described previously. 8 In brief, ATRA 45 mg/m 2 was prescribed as remission induction therapy without concomitant full-dose chemotherapy. Complete blood cell count, white blood cell (WBC) classification and biochemistry were regularly followed. RA syndrome was defined as the presence of unexplained fever, respiratory distress, pleuro-pericardial effusion, pulmonary infiltration, and weight gain after the start of ATRA. Twenty-one patients achieved a CR after ATRA therapy. Fourteen of them received two or more courses of conventional consolidation chemotherapy with anthracycline-containing regimen and two received only one course. Three patients refused chemotherapy and two received low-dose cytarabine. Until July 1998, 13 patients, including seven of 14 patients treated with two or more courses of conventional consolidation chemotherapy and six of seven patients without intensive treatment, finally relapsed. All these recurrent patients were subjected to our analysis.
Patients treated with chemotherapy alone -historical control
From 1988 to 1991, 22 APL patients were treated with standard induction chemotherapy of '3+7' regimen (14 cases) or with low-dose cytarabine chemotherapy (eight cases). Sixteen patients achieved a CR, and 10 of them received standard consolidation chemotherapy. Eleven patients relapsed. The sites of recurrence in these patients were compared with those in the 13 relapsed patients previously treated with ATRA mentioned above.
Results
Clinical and laboratory characters of the 13 relapsed patients with prior ATRA induction treatment are listed in Table 1 . Three patients with extramedullary recurrence were identified (cases 7, 11 and 12), compared with none in the 11 relapsed patients previously treated with chemotherapy alone (estimated relative risk 2.100, 95% confidence interval 1.341-3.289). When all patients achieving complete remission were analyzed, more extramedullary relapse was also found in the group with ATRA induction than in that with conventional chemotherapy induction alone (three in 21 patients vs none in 16 patients, estimated relative risk 1.889, 95% confidence interval 1.376-2.593). One patient had nasopharynx involvement, one, central nerve system (CNS), and the remaining one, CNS and buttock muscle in two episodes, respectively. Among the 13 relapsed patients previously treated with ATRA, five patients had the complication of RA syndrome during induction and three of them developed extramedullary relapse, while none of the remaining eight patients without RA syndrome had the same condition (estimated relative risk 5.000, 95% confidence interval 1.448-17.271). Other clinical or biological parameters including age, sex, WBC count, surface antigen expression (such as CD13), morphological variants and isoforms of PML/RAR␣ had no implications on the risk of extramedullary recurrence.
Discussion
Extramedullary involvement of APL is extremely uncommon. Less than 30 cases have been reported in the literature until now and the diagnosis in most of these cases was not confirmed by cytogenetic or molecular studies. 6, 7, 9 However, since the first report by Weiss and Warrell, 5 extramedullary relapses in APL patients receiving ATRA induction have been detected more frequently than before, 6,7,10 but the correlation between ATRA usage and the subsequent extramedullary disease remains obscure. In this retrospective study, it was demonstrated that patients receiving ATRA induction had an increased risk in extramedullary relapse compared with those with chemotherapy alone. It was also shown that the occurrence of RA syndrome during ATRA treatment was a significant risk factor for extramedullary involvement at relapse, which had not been reported before. Further studies are needed to confirm this finding. WBC count at diagnosis or after ATRA treatment, which was closely associated with the development of RA syndrome, 8 was not clearly linked to extramedullary relapse, probably due to small sample size. Although the patients received heterogenous regimen of consolidation, there was no relationship between the consolidation regimen and the occurrence of extramedullary diseases. In fact, all three patients with extramedullary relapse had received at least two courses of anthracycline-containing consolidation chemotherapy.
RA syndrome represents a process where APL cells infiltrate multiple tissues and organs including lung, skin, etc. during cell differentiation. 4 This phenomenon may, in part, be linked to the modulation of certain adhesion molecules such as CD56, CD18 (leukocyte adhesion protein b), and ICAM-1 in endothelial cells and leukemic cells during ATRA treatment. 7, 11 Tissues infiltrated by leukemic cells may be potential sanctuary sites for these cells during subsequent consolidation chemotherapy. This might explain why the occurrence of RA syndrome was a powerful predictor for subsequent development of extramedullary disease as shown in this study. CD13 (aminopeptidase N) was demonstrated to be correlated with the invasion capacity of leukemic cells. 12 It was suggested that increased expression of CD13 on leukemic cells after ATRA treatment might play some role in the pathogenesis of RA syndrome and extramedullary recurrence. 6, 13 In the current study, most APL patients had CD13 expression on their leukemic cells (Table 1) , so it was impossible to analyze the correlation between CD13 expression and extramedullary involvement.
No concurrent full-dose chemotherapy was prescribed to APL patients during ATRA treatment in our institution previously, no matter whether there was leukocytosis or not. 8 The incidence of RA syndrome was 36%, 8 which was similar to that in Western centers where concurrent chemotherapy was not routinely used, 14 but higher than that of the series with concurrent application of chemotherapy to patients with leukocytosis. 15 The high incidence of RA syndrome in our series gave us a chance to observe the influence of RA syndrome in the outcome of the patients. Although the number of patients is small, the increased risk of extramedullary relapse in patients who developed RA syndrome during prior ATRA induction treatment should be seen as a warning which deserves further investigation. It is also suggested that concurrent chemotherapy should be given with ATRA in the induction treatment of APL to decrease the incidence of RA syndrome, and possibly the chance of extramedullary relapse. Recently, it was reported that concurrent administration of ATRA and chemotherapy reduced the relapse rate compared to sequential ATRA followed by chemotherapy. 16 However, it was not mentioned whether there are differences in the incidence of RA syndrome and the relapse sites between the two groups of patients.
In conclusion, ATRA usage may increase the risk of subsequent extramedullary relapse, especially when RA syndrome develops during remission induction. Whether different treatment strategies, such as high-dose consolidation chemotherapy with CNS prophylaxis or hemopoietic stem cell transplantation in first CR should be used in those patients with RA syndrome during ATRA induction remains to be determined.
